Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Danyelza |
|---|---|
| Manufacturer | Y-mAbs Therapeutics |
| Prescription required | Yes |
Danyelza 4mg/ml injection 1vial x 10ml(naxitamab-gqgk)
naxitamab-gqgk
Description
Danyelza 4mg/ml injection 1vial x 10ml(naxitamab-gqgk) is a medicine catalog record in the MediPriceHub database. Active ingredient: naxitamab-gqgk. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Y-mAbs Therapeutics. Therapeutic category: Medicine Library > Oncology Medicines > Cytoma drugs. Pack information: 40 / 10 (4 / ). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).How to Use
Use naxitamab-gqgk under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: naxitamab-gqgk. Pack size: 40 / 10 (4 / ). Pack unit: bottle. Manufacturer: Y-mAbs Therapeutics. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Cytoma drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.Esta información es solo orientativa. Consulta a un profesional sanitario antes de usar cualquier medicamento.